Abstract summary 

Previous results demonstrated that and gene variants affect serum concentrations of antidepressants. We implemented a PGx service determining gene variants in and in our clinical routine care and report on our first patient cohort.We analyzed and allele, genotype, and phenotype frequencies, and actionable pharmacogenetic variants in this German psychiatric inpatient cohort. Two-tailed z-test was used to investigate for differences in and phenotypes and actionable/non-actionable genetic variant frequencies between our cohort and reference cohorts.Out of the 154 patients included, 44.8% of patients were classified as CYP2D6 normal metabolizer, 38.3% as intermediate metabolizers, 8.4% as poor metabolizers, and 2.6% as ultrarapid metabolizers. As for CYP2C19, 40.9% of patients were classified as normal metabolizers, 19.5% as intermediate metabolizers, 2.6% as poor metabolizers, 31.2% as rapid metabolizers, and 5.8% as ultrarapid metabolizers. Approximately 80% of patients had at least one actionable PGx variant.There is a high prevalence of actionable PGx variants in psychiatric inpatients which may affect treatment response. Physicians should refer to PGx-informed dosing guidelines in carriers of these variants. Pre-emptive PGx testing in general may facilitate also for other drugs metabolized by CYP2D6 and/or CYP2C19.

Authors & Co-authors:  Scherf-Clavel Weber Unterecker Müller Deckert

Study Outcome 

Source Link: Visit source